CG Oncology advancing clinical-stage urologic oncology immunotherapy pipeline
webmaster2022-12-06T19:23:30+00:00Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...